PathWhiz ID | Pathway | Meta Data |
---|---|---|
PW147059View Pathway |
Trolamine Drug Metabolism PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 10, 2023 at 13:46 Last Updated: October 10, 2023 at 13:46 |
PW146119View Pathway |
drug action
Trolamine polypeptide oleate condensate Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 17:27 Last Updated: October 07, 2023 at 17:27 |
PW127675View Pathway |
drug action
Trolamine salicylate Action PathwayHomo sapiens
Trolamine salicylate is a nonsteroidal anti-inflammatory agent (NSAID) used for the temporary relief of some minor aches and pains of the muscles and joints associated with backache, lumbago, strains, bruises, sprains, and arthritic or rheumatic pain, pain of tendons and ligaments. This drug is used as a topical analgesic. It targets the prostaglandin G/H synthase-1 (COX-1) and prostaglandin G/H synthase-2 (COX-2) in the cyclooxygenase pathway. The cyclooxygenase pathway begins in the cytosol with phospholipids being converted into arachidonic acid by the action of phospholipase A2. The rest of the pathway occurs on the endoplasmic reticulum membrane, where prostaglandin G/H synthase 1 & 2 convert arachidonic acid into prostaglandin H2. Prostaglandin H2 can either be converted into thromboxane A2 via thromboxane A synthase, prostacyclin/prostaglandin I2 via prostacyclin synthase, or prostaglandin E2 via prostaglandin E synthase. COX-2 is an inducible enzyme, and during inflammation, it is responsible for prostaglandin synthesis. It leads to the formation of prostaglandin E2 which is responsible for contributing to the inflammatory response by activating immune cells and for increasing pain sensation by acting on pain fibers. Trolamine salicylate inhibits the action of COX-1 and COX-2 on the endoplasmic reticulum membrane. This reduces the formation of prostaglandin H2 and therefore, prostaglandin E2 (PGE2). The low concentration of prostaglandin E2 attenuates the effect it has on stimulating immune cells and pain fibers, consequently reducing inflammation and pain.
|
Creator: Daphnee Created On: May 19, 2023 at 10:35 Last Updated: May 19, 2023 at 10:35 |
PW132260View Pathway |
Trolamine salicylate Drug MetabolismHomo sapiens
Trolamine salicylate is a drug that is not metabolized by the human body as determined by current research and biotransformer analysis. Trolamine salicylate passes through the liver and is then excreted from the body mainly through the kidney.
|
Creator: Ray Kruger Created On: September 21, 2023 at 20:26 Last Updated: September 21, 2023 at 20:26 |
PW146219View Pathway |
drug action
Trolamine salicylate Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 17:42 Last Updated: October 07, 2023 at 17:42 |
PW124332View Pathway |
drug action
Troleandomycin Action Pathway (New)Bacteria
Troleandomycin is a macrolide antibiotic used for the treatment of bacterial infections of the upper and lower respiratory tract such as tonsilitis, bronchitis, sinusitis and pneumonia. Troleandomycin targets the protein synthesis machinery in the bacterial cytoplasm to inhibit protein synthesis and prevent bacterial growth. Troleandomycin enters through the bacterial cell membrane through multidrug resistant protein 1 and binds to the bacterial ribosome. The bacterial ribosome consists of two subunits: the 50s and the 30s subunit. Troleandomycin binds to the 50s subunit and prevents translocation of the tRNA along the A, P and E sites of the ribosome. Translocation of amino acids from the acceptor site (A site) to the donor site (P site) is prevented and as a result, protein synthesis is halted. The bacterial cells are unable to generate proteins necessary for growth and duplication, therefore, growth of the bacteria is inhibited. Side effects from taking troleandomycin may include abdominal cramping and discomfort, nausea and vomiting, diarrhea, dizziness, fatigue, headache, vaginal yeast infection and allergic reactions including urticaria, skin rashes and anaphylaxis.
|
Creator: Karxena Harford Created On: November 10, 2020 at 20:45 Last Updated: November 10, 2020 at 20:45 |
PW000707View Pathway |
drug action
Troleandomycin Action PathwayHomo sapiens
Troleandomycin, sold as Triocetin and Tekmisin, is a macrolide antibiotic drug. It is similar to erythromycin, the first macrolide discovered, as well as azithromycin and clarithromycin, which were formed from chemically modified erythromycin. As with other macrolides, troleandomycin binds to the bacterial ribosome, preventing ribosomal translation from occurring, as well as preventing amino acids from being added to the protein during protein biosynthesis. This prevents the bacteria from being able to produce potentially vital proteins, and means that the bacteria will likely die.
Troleandomycin may inhibit some Cytochrome P450 enzymes, leading to averse effects to other drugs.
Troleandomycin is used to treat pneumonia and streptococcal infection, but it is not yet FDA approved and is only currently used in Turkey.
|
Creator: WishartLab Created On: June 23, 2014 at 04:02 Last Updated: June 23, 2014 at 04:02 |
PW146603View Pathway |
drug action
Troleandomycin Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 18:36 Last Updated: October 07, 2023 at 18:36 |
PW176501View Pathway |
Troleandomycin Predicted Metabolism PathwayHomo sapiens
Metabolites of Troleandomycin are predicted with biotransformer.
|
Creator: Omolola Created On: December 13, 2023 at 12:53 Last Updated: December 13, 2023 at 12:53 |
PW146640View Pathway |
drug action
Tromantadine Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 18:42 Last Updated: October 07, 2023 at 18:42 |